1. Salt and blood pressure: What’s new?

   • Myron H. Weinberger

   Invited Commentary Pages: 271 - 272

2. Web alert

   News Pages: 273 - 274

3. Literature alert

   Abstract Pages: 275 - 276

4. When can treatment of hypertension be stopped?

   • Michael A. Weber

   Clinical Trials Report Pages: 279 - 280

5. Statins and blood pressure regulation

   • Claudio Borghi
   • Maddalena Veronesi
   • Ettore Ambrosioni

   OriginalPaper Pages: 281 - 288

6. The INSIGHT and NORDIL trials: Are calcium antagonists equivalent to established drug therapies for cardiovascular protection?

   • Michael C. Ruddy

   OriginalPaper Pages: 289 - 296

7. The effect of antihypertensive drugs on vascular compliance

   • Nathaniel Winer
   • Michael A. Weber
   • James R. Sowers

   OriginalPaper Pages: 297 - 304

8. Do most antihypertensive agents have a sympatholytic action?

   • Jacques de Champlain

   OriginalPaper Pages: 305 - 313

9. Central sympathoinhibitory effects of calcium channel blockers

   • Frans H. H. Leenen
   • Marcel Ruzicka
   • Bing S. Huang

   OriginalPaper Pages: 314 - 321

10. The therapeutic potential of endothelin receptor antagonists in cardiovascular disease

    • Matthias Barton
    • Wolfgang Kiowski

    OriginalPaper Pages: 322 - 330

11. The benefit of treating isolated systolic hypertension

    • Ji-Guang Wang
    • Jan A. Staessen

    OriginalPaper Pages: 333 - 339

12. Prospectively designed overviews of recent trials comparing antihypertensive regimens based on different drug classes

    • Neil Chapman
    • Bruce Neal

    OriginalPaper Pages: 340 - 349

13. The antiatherogenic effects of antihypertensive treatment: Trials completed and ongoing

    • Alberto Zanchetti

    OriginalPaper Pages: 350 - 359

14. Lessons learned from prematurely terminated clinical trials

    • Domenic Sica

    OriginalPaper Pages: 360 - 366